Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$160.39 USD
+0.34 (0.21%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $160.91 +0.52 (0.32%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Brokerage Reports
Alnylam Pharmaceuticals, Inc. [ALNY]
Reports for Purchase
Showing records 261 - 280 ( 410 total )
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Monsanto Alliance Brings in Additional Non-Dilutive Capital
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Monsanto Alliance Brings in Additional Non-Dilutive Capital
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Reports 2Q12 Results and Reviews Recent Clinical Successes
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Reports 2Q12 Results and Reviews Recent Clinical Successes
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Progress of the VaxiRNA Program Illustrates the Robustness
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Progress of the VaxiRNA Program Illustrates the Robustness
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Hemophilia Program Takes Shape, Bolstered by GalNac Delivery Platform
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Hemophilia Program Takes Shape, Bolstered by GalNac Delivery Platform
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Upcoming TTR-02 Data Should Provide Near-Term Catalyst to ALNY Shares
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M